Strong Eczema Response To JAK Inhibitor- Charles Bankhead
Patients with moderate or severe atopic dermatitis (AD) had as much as 74 percent improvement in disease status with the oral Janus kinase (JAK) inhibitor upadacitinib, a randomized trial showed. Across the range of doses tested, upadacitinib had a favorable safety profile, reported lead investigator Emma Guttman-Yassky, PhD, professor of dermatology and clinical immunology, vice chair of research in the department of dermatology and the director of the Center for Excellence in Eczema at the Icahn School of Medicine at Mount Sinai, at the American Academy of Dermatology meeting. "The emerging positive benefit/risk profile observed for upadacitinib in atopic dermatitis supports proceeding with phase III trials," Dr. Guttman-Yassky concluded. Upadacitinib is a once-daily, oral JAK1-selective inhibitor under evaluation for several inflammatory diseases and the FDA recently granted breakthrough therapy status for the drug.
- Emma Guttman-Yassky, MD, PhD, The Sol & Clara Professor, Dermatology, Clinical Immunology, Medicine, Vice Chair, Research, Department of Dermatology, Director, The Center for Excellence in Eczema, Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai
Learn more
Additional coverage:
AAD Meeting News
Dermatology Times
Street Insider